The Affiliated Company scheme, established in October 2017, now includes 64 organizations which bring diverse expertise and resource to the Milner network.
The institute promotes interactions between affiliated companies and academic, pharmaceutical or bio-technology partners, with the aim of building a cohesive community with an aligned vision. Our annual symposium is a key event — supported by the affiliated companies — for catalysing new opportunities for collaboration.
The affiliated companies include global pharma and biotech companies as well as a significant number of start-ups and SMEs with their own drug pipeline, many of which have arisen from research in Cambridge. Our activities are supported by a broad range of life science companies providing essential drug discovery expertise. The affiliate companies span disease areas from cancer and neurodegeneration to rare disease and there is a strong cohort of companies focusing on AI and data science, emphasizing the rapidly increasing application of this technology in biomedical research.